Related Experiment Video
Updated: Jan 26, 2026

Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
Published on: May 12, 2019
Baicalein Inhibits Orthotopic Human Non-Small Cell Lung Cancer Xenografts via Src/Id1 Pathway
Zhengxiao Zhao1, Baojun Liu1,2, Jing Sun1,2
1The Department of Integrative Medicine, Huashan Hospital, Fudan University, 12 Middle Urumqi Road, Shanghai 200040, China.
Abstract:
Non-small cell lung cancer (NSCLC) is one of the most lethal cancers worldwide. Inhibitor of differentiation 1 (Id1) is the member mostly linked to tumorigenesis in Id family and a potential molecular target in cancer therapy. In the current study, we established an orthotopic lung cancer model by injecting athymic nude mice with A549 cells and evaluated the antitumor effect of baicalein and expression of Id1-related proteins in vivo and in vitro. Micro-CT images showed that tumor volume in baicalein group was significantly reduced. Western blot analysis revealed that baicalein suppressed the expression of Id1 protein, epithelial-to-mesenchymal transition (EMT) related molecules (N-Cadherin, vimentin), and angiogenesis related protein (VEGF-A), accompanied by upregulation of epithelial markers (such as E-cadherin). In addition, phosphorylation of upstream molecular Src was significantly restrained after baicalein treatment. This study firstly demonstrates that baicalein inhibits tumor growth in orthotopic human NSCLC xenografts via targeting Src/Id1 pathway.
Insights
Baicalein effectively reduces non-small cell lung cancer (NSCLC) tumor growth by targeting the Src/Id1 pathway. This natural compound inhibits key proteins involved in tumor progression and blood vessel formation.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality globally.
- Inhibitor of differentiation 1 (Id1) is implicated in cancer development and serves as a potential therapeutic target.
- Understanding novel therapeutic strategies for NSCLC is crucial.
Purpose of the Study:
- To investigate the antitumor effects of baicalein in an orthotopic NSCLC model.
- To elucidate the molecular mechanisms underlying baicalein's action, focusing on the Src/Id1 pathway.
Main Methods:
- Establishment of an orthotopic NSCLC xenograft model using A549 cells in athymic nude mice.
- Administration of baicalein and evaluation of antitumor effects via Micro-CT imaging.
- Analysis of protein expression (Id1, EMT markers, VEGF-A, E-cadherin) and Src phosphorylation using Western blot.
Main Results:
- Baicalein significantly reduced tumor volume in the orthotopic NSCLC model.
- Baicalein suppressed Id1 expression, epithelial-to-mesenchymal transition (EMT) markers (N-Cadherin, vimentin), and VEGF-A.
- Baicalein treatment led to upregulation of epithelial markers (E-cadherin) and inhibition of Src phosphorylation.
Conclusions:
- Baicalein exhibits significant antitumor activity against human NSCLC xenografts.
- The study demonstrates that baicalein targets the Src/Id1 pathway to inhibit tumor growth, EMT, and angiogenesis.
- Baicalein represents a promising therapeutic agent for NSCLC treatment.
More Related Videos
Related Concept Videos
Feedback Inhibition
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Lung Capacity
Enzyme Inhibition
Other Glycolytic Pathways
Inhibition of Cdk Activity

